PCFTF Stock News Pacific Therapeutics (PCFTF) 0.0509 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pacific Therapeutics (PCFTF) 0.0509 $PCFTF

Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Pacific Therapeutics and Vodis Innovative Pharmaceuticals Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Thu Jul 17, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" The Company is pleased to announce that it has signed a term sheet with Vodis Innovative Pharmaceuticals ("Vodis" agreeing to work with Vodis on the development of therapies based on extracts from cannabis plants.

FDA to Host Meeting on Patient Focused Drug Development for IPF
ACCESSWIRE - Wed Jul 16, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" The FDA registered notice in the July 8, 2014 edition of the Federal Register that on September 26, 2014, the FDA is conducting a public meeting on Patient-Focused Drug Development for idiopathic pulmonary fibrosis (IPF). FDA is interested in obtaining patient input on the impact of IPF on daily life and patients' views on currently available therapies to treat the condition.

Expiry of Chinese Patent for Erectile Dysfunction Drug Opens Additional Market Opportunity
ACCESSWIRE - Fri Jul 11, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 11, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" The potential market for the Company's erectile dysfunction (ED) treatment is set to grow with the expiry of the Chinese patent on the leading ED treatment set for July.

Combination Treatment for Pulmonary Fibrosis Demonstrates Significant Disease Improvement in Pre-Clinical Trial
ACCESSWIRE - Wed Jul 09, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.

European Patent Office Grants Patent for PTL-202, a Treatment for Idiopathic Pulmonary Fibrosis, a $1.1 Billion Opportunity
ACCESSWIRE - Mon Jul 07, 7:32AM CDT
VANCOUVER, BC / ACCESSWIRE / July 7, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF), (IPF Coalition). IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6% (RnR Market Research, 2013). IPF kills more patients per year than either prostate or breast cancer.

Pacific Therapeutics Plans For Clinical Trial Timely In Light of Increasing Prevalence of Pulmonary Fibrosis
ACCESSWIRE - Thu Jul 03, 1:53AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for diseases of excessive scarring (fibrosis) and erectile dysfunction commented today that ongoing preparations for its planned clinical trials appear to be timely as recent reports in the scientific literature point toward an ever-increasing incidence of Idiopathic Pulmonary Fibrosis (IPF).

Pacific Therapeutics Announces Directors Options
ACCESSWIRE - Fri Jun 27, 3:35PM CDT
VANCOUVER, BC / ACCESSWIRE / June 27, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.

Liver Cirrhosis - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tdw2pl/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Nitto Denko Corporation - Galectin Therapeutics, Inc. - Digna Biotech, S.L. - Phenex Pharmaceuticals AG - Tobira Therapeutics, Inc. - GNI Group Ltd. - Alfa Wassermann S.p.A - Pharmicell Co., Ltd. - PharmaIN Corporation - Stempeutics Research Private Limited - Pacific Therapeutics Ltd. - ACROVIS biostructures GmbH For more information visit http://www.researchandmarkets.com/research/td..._cirrhosis

Pacific Therapeutics Announces First Quarter 2014 Financial Results
ACCESSWIRE - Fri May 30, 7:15PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / May 30, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on erectile dysfunction and diseases of excessive scarring (fibrosis) which are $1 billion plus market opportunities.

Pacific Therapeutics Signs Agreement with Broker Dealer Tripoint Global Equities LLC.
ACCESSWIRE - Thu May 15, 7:35AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / May 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

International Isotopes Enhances Growth with New Facilities

Updated Category News Views 139

International Isotopes Expands Its Operational Footprint International Isotopes, Inc. (OTCQB: INIS) has announced a significant expansion of its operational capabilities with a strategic land acquisition and a new facility lease agreement. This initiative is part of a broader strategy aimed at enhancing the Company's footprint in the radiopharmaceuticals sector. Strategic...

Continue Reading
Humana Achieves Top Honors in Customer Experience Again

Updated Category News Views 80

Humana Excels in Customer Experience for Four Straight Years Humana has once again secured the top position in customer experience among health insurers, according to a recent survey conducted by Forrester. This marks the fourth consecutive year that Humana has achieved this prestigious recognition, reaffirming its commitment to delivering exceptional service and care to...

Continue Reading
BrainStorm Cell Therapeutics Presents Insights into ALS Treatment

Updated Category News Views 128

BrainStorm Cell Therapeutics Webinar on ALS Treatments BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent innovator in adult stem cell therapeutics for neurodegenerative diseases, will be hosting an insightful webinar on current developments in treating amyotrophic lateral sclerosis (ALS). This event is designed to provide essential updates and perspectives...

Continue Reading
Celebrating Excellence: The 2024 Employer Branding Awards Unveiled

Updated Category News Views 235

Overview of the Employer Branding Creativity Awards The "2024 Employer Branding Creativity Awards" organized by the Employer Branding Institute, recognized 75 exemplary companies for their innovative contributions to employer branding. Sponsored by Jaguar Land Rover China, this prestigious event not only celebrates creativity but also demonstrates the rising influence of...

Continue Reading
Battery Recycling Market Expected to Hit $77.1 Billion by 2034

Updated Category News Views 210

Battery Recycling Market Overview The battery recycling market is gaining remarkable traction worldwide, projected to soar to $77.1 billion by 2034. This forecast represents a significant growth trajectory from a valuation of $26.9 billion in 2024, indicating a compound annual growth rate (CAGR) of 11.2% from 2025 to 2034. Impact of Government Regulations Government...

Continue Reading